STEINMAN LAWRENCE - 08 Dec 2021 Form 4 Insider Report for 180 Life Sciences Corp. (ATNF)

Role: Director
Signature: /s/ Lawrence Steinman, M.D.
Issuer symbol: ATNF
Transactions as of: 08 Dec 2021
Transactions value $: $21,350
Form type: 4
Filing time: 10 Dec 2021, 07:22:39 UTC
Previous filing: 03 Nov 2021
Next filing: 17 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ATNF	Common Stock	Purchase	$21,350	+5,000	+0.84%	$4.27^*	602,574	09 Dec 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATNF	Stock Option (Right to Buy)	Award	$0	+25,000		$0	25,000	08 Dec 2021	Common Stock	25,000	$3.95	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was executed in multiple trades at prices ranging from $4.24 to $4.28. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F2	Granted to the Reporting Person pursuant to the Issuer's 2020 Omnibus Incentive Plan in consideration for services to be rendered. Exempt from Section 16(b) of the Securities Exchange Act of 1934 under Rule 16b-3.

Content

This transaction was executed in multiple trades at prices ranging from $4.24 to $4.28. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Granted to the Reporting Person pursuant to the Issuer's 2020 Omnibus Incentive Plan in consideration for services to be rendered. Exempt from Section 16(b) of the Securities Exchange Act of 1934 under Rule 16b-3.